News
IBI3030 significantly reduces LDL-c (p<0.01 vs. baseline) and Lp(a), improves oral glucose tolerance (OGTT) (effective even in GLP-1R knockout mice), reduces body weight, and preserves insulin ...
Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.
More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...
GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferences—leading to weight loss beyond just reduced appetite.
A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...
A common diabetes drug may be the next big thing for migraine relief. In a clinical study, obese patients with chronic ...
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...
In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...
GLP-1 agonists have gained recent widespread attention, reshaping treatment approaches for several diseases, including diabetes and cardiovascular disease. 2 In the treatment of type 2 diabetes, ...
GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results